Published in Elife on October 13, 2015
Transparent reporting of research results in eLife. Elife (2016) 0.97
High-content screening identifies kinase inhibitors that overcome venetoclax resistance in activated CLL cells. Blood (2016) 0.87
The Researchers' View of Scientific Rigor-Survey on the Conduct and Reporting of In Vivo Research. PLoS One (2016) 0.83
Authorization of Animal Experiments Is Based on Confidence Rather than Evidence of Scientific Rigor. PLoS Biol (2016) 0.82
Is Participation in Cancer Phase I Trials Really Therapeutic? J Clin Oncol (2016) 0.78
Optimized design and analysis of preclinical intervention studies in vivo. Sci Rep (2016) 0.75
Consider drug efficacy before first-in-human trials. Nature (2017) 0.75
Design and Reporting of Targeted Anticancer Preclinical Studies: A Meta-Analysis of Animal Studies Investigating Sorafenib Antitumor Efficacy. Cancer Res (2016) 0.75
Developing translational medicine professionals: the Marie Skłodowska-Curie action model. J Transl Med (2016) 0.75
Drug therapy: Preclinical oncology - reporting transparency needed. Nat Rev Clin Oncol (2015) 0.75
The Devil Is in the Details: Incomplete Reporting in Preclinical Animal Research. PLoS One (2016) 0.75
The pancreatic niche inhibits the effectiveness of sunitinib treatment of pancreatic cancer. Oncotarget (2016) 0.75
Sex-Divergent Clinical Outcomes and Precision Medicine: An Important New Role for Institutional Review Boards and Research Ethics Committees. Front Pharmacol (2017) 0.75
Meta-analysis in clinical trials. Control Clin Trials (1986) 144.91
THE ENVIRONMENT AND DISEASE: ASSOCIATION OR CAUSATION? Proc R Soc Med (1965) 40.52
Improving bioscience research reporting: the ARRIVE guidelines for reporting animal research. PLoS Biol (2010) 27.58
Drug development: Raise standards for preclinical cancer research. Nature (2012) 20.64
Overall survival and updated results for sunitinib compared with interferon alfa in patients with metastatic renal cell carcinoma. J Clin Oncol (2009) 13.52
Sunitinib malate for the treatment of pancreatic neuroendocrine tumors. N Engl J Med (2011) 11.93
Sunitinib in patients with metastatic renal cell carcinoma. JAMA (2006) 11.33
Activity of SU11248, a multitargeted inhibitor of vascular endothelial growth factor receptor and platelet-derived growth factor receptor, in patients with metastatic renal cell carcinoma. J Clin Oncol (2005) 9.05
The case of the misleading funnel plot. BMJ (2006) 8.26
Survey of the quality of experimental design, statistical analysis and reporting of research using animals. PLoS One (2009) 7.60
Sunitinib: from rational design to clinical efficacy. J Clin Oncol (2007) 7.26
1,026 experimental treatments in acute stroke. Ann Neurol (2006) 7.23
Safety, pharmacokinetic, and antitumor activity of SU11248, a novel oral multitarget tyrosine kinase inhibitor, in patients with cancer. J Clin Oncol (2005) 7.12
Update of the stroke therapy academic industry roundtable preclinical recommendations. Stroke (2009) 6.79
Can animal models of disease reliably inform human studies? PLoS Med (2010) 6.27
Relationships between drug activity in NCI preclinical in vitro and in vivo models and early clinical trials. Br J Cancer (2001) 5.58
Reducing waste from incomplete or unusable reports of biomedical research. Lancet (2014) 5.37
Clinical development success rates for investigational drugs. Nat Biotechnol (2014) 5.32
Estimating the cost of new drug development: is it really 802 million dollars? Health Aff (Millwood) (2006) 4.84
Pooling of animal experimental data reveals influence of study design and publication bias. Stroke (2004) 4.37
Relationship between exposure to sunitinib and efficacy and tolerability endpoints in patients with cancer: results of a pharmacokinetic/pharmacodynamic meta-analysis. Cancer Chemother Pharmacol (2009) 3.53
Clinical predictive value of the in vitro cell line, human xenograft, and mouse allograft preclinical cancer models. Clin Cancer Res (2003) 3.30
Empirical evidence of bias in the design of experimental stroke studies: a metaepidemiologic approach. Stroke (2008) 2.98
Meta-Analyst: software for meta-analysis of binary, continuous and diagnostic data. BMC Med Res Methodol (2009) 2.92
Evaluation of excess significance bias in animal studies of neurological diseases. PLoS Biol (2013) 2.70
Human tumor xenografts as predictive preclinical models for anticancer drug activity in humans: better than commonly perceived-but they can be improved. Cancer Biol Ther (2003) 2.61
Six red flags for suspect work. Nature (2013) 2.51
Reproducibility in science: improving the standard for basic and preclinical research. Circ Res (2015) 2.32
A search filter for increasing the retrieval of animal studies in Embase. Lab Anim (2011) 2.09
Enhancing search efficiency by means of a search filter for finding all studies on animal experimentation in PubMed. Lab Anim (2010) 2.05
Integrating pharmacology and in vivo cancer models in preclinical and clinical drug development. Eur J Cancer (2004) 1.92
Direct and differential suppression of myeloid-derived suppressor cell subsets by sunitinib is compartmentally constrained. Cancer Res (2010) 1.92
Threats to validity in the design and conduct of preclinical efficacy studies: a systematic review of guidelines for in vivo animal experiments. PLoS Med (2013) 1.92
How good are rodent models of carcinogenesis in predicting efficacy in humans? A systematic review and meta-analysis of colon chemoprevention in rats, mice and men. Eur J Cancer (2005) 1.85
Dopamine agonists in animal models of Parkinson's disease: a systematic review and meta-analysis. Parkinsonism Relat Disord (2011) 1.64
Preclinical evaluation of the tyrosine kinase inhibitor SU11248 as a single agent and in combination with "standard of care" therapeutic agents for the treatment of breast cancer. Mol Cancer Ther (2003) 1.61
The Lambeth Conventions (II): guidelines for the study of animal and human ventricular and supraventricular arrhythmias. Pharmacol Ther (2013) 1.50
Identification of new epilepsy treatments: issues in preclinical methodology. Epilepsia (2012) 1.45
Methodological quality of animal studies on neuroprotection in focal cerebral ischaemia. J Neurol (2005) 1.23
Initial testing (stage 1) of sunitinib by the pediatric preclinical testing program. Pediatr Blood Cancer (2008) 1.20
Reproducibility of research and preclinical validation: problems and solutions. Nat Rev Clin Oncol (2013) 1.20
Time to do something about reproducibility. Elife (2014) 1.16
Systematic review and meta-analysis of temozolomide in animal models of glioma: was clinical efficacy predicted? Br J Cancer (2013) 1.16
A phase II study of sunitinib in patients with relapsed or refractory small cell lung cancer. Lung Cancer (2012) 1.07
A proposal regarding reporting of in vitro testing results. Clin Cancer Res (2013) 1.06
What is the translational efficacy of chemotherapeutic drug research in neuro-oncology? A systematic review and meta-analysis of the efficacy of BCNU and CCNU in animal models of glioma. J Neurooncol (2008) 0.95
Reporting of preclinical tumor-graft cancer therapeutic studies. Cancer Biol Ther (2012) 0.85
An unappreciated challenge to oncology drug discovery: pitfalls in preclinical research. Am Soc Clin Oncol Educ Book (2013) 0.84
YM-359445, an orally bioavailable vascular endothelial growth factor receptor-2 tyrosine kinase inhibitor, has highly potent antitumor activity against established tumors. Clin Cancer Res (2006) 0.83
Budgets up at NIH, NCI, and FDA. Cancer Discov (2014) 0.77
Why clinical translation cannot succeed without failure. Elife (2015) 0.77